Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Functional assessment of the Preserflo MicroShunt implant in pigmentary glaucoma: 2 years follow-up.
Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preserflo microshunt outcomes in pigmentary glaucoma: a propensity score-matched comparison with primary open-angle glaucoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the clinical outcomes of Preserflo MicroShunt (PMS) implantation with mitomycin C (MMC) in the management of pigmentary glaucoma (PG).
methodsRetrospective observational study. All consecutive patients diagnosed with PG who underwent PMS implantation with at least 24 months of follow-up were included. Primary outcomes included postoperative intraocular pressure (IOP), number of hypotensive medications, surgical success, defined as IOP < 18 mmHg with a reduction of ≥ 20% from baseline without the need for further surgery and no severe surgery-related complications. ‘Complete success’ was defined as achieving target IOP without medications; ‘qualified success’ allowed the use of medications.
resultsFourteen eyes from 10 patients (mean age 60.8 ± 11.8 years) were included. Mean IOP was significantly reduced from 23.8 ± 6.0 mmHg at baseline to 14.9 ± 4 mmHg at 12 months and to 15.4 ± 2.7 at 24 months (both p < 0.001). The mean number of glaucoma medications per patient decreased from 2.9 ± 1 at baseline to 0.5 ± 0.8 at 12 months ( p = 0.002) and to 1 ± 0.9 at 24 months (p = 0.003). At 24 months, 35.7% of patients (n = 5) were medication-free. Overall success at 12 and 24 months was 71.4%, with complete success achieved in 50% at 12 months and 28.6% at 24 months. No sight-threatening complications were observed. No cases required bleb revision.
conclusionOur results suggests that PMS is a safe and effective surgical option for the treatment of PG.
Indexed as
Identifiers
41701317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.